Bringing the Oncology Community Together

Janet Hampton Describes the Distress Thermometer

Janet Hampton, RN, BS
Published Online: Monday, May 23, 2011
Janet Hampton, RN, BS, OCN® from the University of Michigan Health System Cancer Center Describes the Distress Thermometer
Related Articles
Dr. Fine on Capecitabine Plus Temozolomide for NETs
Robert L. Fine, MD, from the Columbia University Medical Center, discusses the prospective phase II study of CAPTEM for patients with neuroendocrine tumors.
Ramucirumab Improves Survival in Advanced Gastric Cancer
Ramucirumab, a monoclonal antibody that targets VEGFR-2, significantly prolonged survival in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma following progression on first-line therapy, according to results from the phase III REGARD study published in The Lancet.
Survival Benefit Observed With Cetuximab  in RAS Wild-Type Colorectal Cancer
Cetuximab plus FOLFIRI may offer a survival advantage over FOLFIRI plus bevacizumab in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer who do not have RAS mutations.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.